Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis
Pigment Cell & Melanoma Research · 2026-01 · 39 (1)
DOI: 10.1111/pcmr.70065 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Pigment Cell & Melanoma Research, online erschienen am 21.01.2026. Verfasst von Zhengyang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Royal Melbourne Hospital, Parkville, Australia. Hauptthemen laut MEDLINE: Lasers, Excimer, Low-Level Light Therapy, Vitiligo. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Excimer 308‐nm light is often used for vitiligo treatment in combination with adjuvants. We aimed to evaluate the efficacy of these combination therapies. We searched MEDLINE, Embase and the Cochrane Library from inception to November 2024. All randomised trials reporting efficacy outcomes for vitiligo patients treated with excimer 308‐nm light were included. Primary outcomes were achieving ≥ 50%, ≥ 75% and 100% skin repigmentation. Pairwise comparisons of treatment repigmentation were summarised as risk ratios (RRs) with 95% confidence intervals (CIs) and a frequentist, random‐effects network meta‐analysis with a graph‐theoretical approach was used to generate summary estimates. Thirty‐eight studies involving 1841 participants were included. Excimer 308‐nm light with topical calcineurin inhibitors or topical corticosteroids significantly improved repigmentation outcomes compared to excimer monotherapy with ≥ 50% (RR 1.47, 95% CI 1.19–1.81; RR 1.65, 95% CI 1.32–2.06) and ≥ 100% repigmentation (RR 1.60, 95% CI 1.03–2.49; RR 2.31, 95% CI 1.50–3.56) respectively. Excimer in combination with topical antioxidants (RR 43.00, 95% CI 2.68–688.68), intramuscular corticosteroid (RR 1.76, 95% CI 1.13–2.74) and platelet rich plasma (RR 1.76, 95% CI 1.32–2.35) enhanced ≥ 50% repigmentation. These findings highlight the value of combination therapy with excimer light as a useful option in the management of vitiligo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Royal Melbourne Hospital, Parkville, Australia.
- Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
- Eastern Health, Melbourne, Australia.
- Skin Health Institute, Melbourne, Australia.
- Victorian Melanoma Service, Alfred Health, Melbourne, Australia.
- Cancer Development and Treatment Laboratory, School of Translational Medicine, Monash University, Melbourne, Australia.
ORCID-Profile: Zhengyang Liu, Wey Han Ng, Samuel Morriss, Zhao Feng Liu, Lawrence Lin, Firdavis Xireaili, Christopher Chew
Zitieren
APA
Liu, Z., Ng, W. H., Morriss, S., Liu, Z. F., Lin, L., Xireaili, F., & Chew, C. (2026). Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis. Pigment Cell & Melanoma Research, 39(1). https://doi.org/10.1111/pcmr.70065
Vancouver
Liu Z, Ng WH, Morriss S, Liu ZF, Lin L, Xireaili F, et al. Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis. Pigment Cell & Melanoma Research. 2026;39(1). doi:10.1111/pcmr.70065
BibTeX
@article{Liu2026,
author = {Liu, Zhengyang and Ng, Wey Han and Morriss, Samuel and Liu, Zhao Feng and Lin, Lawrence and Xireaili, Firdavis and Chew, Christopher},
title = {Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis},
journal = {Pigment Cell & Melanoma Research},
year = {2026},
volume = {39},
number = {1},
doi = {10.1111/pcmr.70065}
}
EUVIMED